ERBB2 and breast carcinoma: We assessed the prognostic value of panels of protein expression levels reflecting differences in activation status of the PI3K/MAPK pathways in ER+/HER2– breast cancer patients as well as of a potential tool to predict the usefulness of adjuvant tamoxifen.